ALTEOGEN Inc (196170) fair value: what the stock is really worth
We calculate from audited financials what ALTEOGEN Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch ALTEOGEN Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 19, 2026.
How to read this chart
60‑month range 28,642 KRW – 558,528 KRW · fair‑value band 54,515 KRW – 195,205 KRW · the 255,000 KRW price screens above the 92,045 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 19, 2026.
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Show more
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Stock analysis
ALTEOGEN Inc (196170) currently trades at 255,000 KRW, while our model-based Fair Value estimate is 92,045 KRW, implying the stock looks roughly 177.0% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 123,001 KRW per share, and 0 of the 24 models we run sit above the 255,000 KRW price.
Bear case: the Growth DCF group reads lowest at 28,111 KRW, and 24 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 54,515 KRW (bear) to 195,205 KRW (bull), the price of 255,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
ALTEOGEN Inc reported revenue of 216B KRW in FY2025 versus 41.1B KRW in FY2021, a compound +51.4%/yr. Reported net income was 142B KRW in FY2025, compounding +120.4%/yr from FY2021.
Key figures
Market cap 14.8T KRW (≈ $10.4B) · P/S ratio 72.6 · Dividend yield 0.1% · Net margin 65.6% · Return on equity 25.2% · Return on assets (EBIT) 2.0% · Operating margin 54.9% · Revenue (TTM) 204B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 55% below its 52-week high, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −64%, 196170 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (5,574 KRW to 125,549 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 54,515 KRWFair Value 92,045 KRWBull 195,205 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+109.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+95.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.5%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+79.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+79.6%
Dividend (yield on the price)0.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 50%
Growth Forecast
Price in line with expectations
The price assumes more growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+48.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+48.9%
Yearly sales growth analysts expect, extended to five years.
News mood ⓘNews mood, the average tone of recent news (38 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 653 stocks
Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside−86% · Bottom 25%
Profitability
Return on equity (TTM)25% · Top 25%
Return on assets8% · Top 25%
Net margin (TTM)64% · Top 25%
Operating margin (TTM)55% · Top 25%
Growth and dividend
Revenue growth−15% · Bottom 25%
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/S (TTM)0.05× · Cheapest 25%
P/FCF0.1× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)100· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)3· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ALTEOGEN Inc Fair Value". https://www.fairvalue-calculator.com/stock/196170
Frequently asked questions
Is ALTEOGEN Inc (196170) overvalued or undervalued?
As of Sep 19, 2026, our model estimates a fair value of 92,045 KRW versus a price of 255,000 KRW, about −64% upside (overvalued).
What is the fair value of 196170?
Our model-based fair value for ALTEOGEN Inc is 92,045 KRW (as of Sep 19, 2026), built from audited fundamentals. The current price: 255,000 KRW.
What is the quality score of 196170?
ALTEOGEN Inc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ALTEOGEN Inc (196170)?
Our model-based price target is the fair value of 92,045 KRW (as of Sep 19, 2026) from 24 valuation models. Cautious scenario 54,515 KRW, optimistic scenario 195,205 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ALTEOGEN Inc stock forecast for 2026?
Our models put fair value at 92,045 KRW, about −64% upside versus a price of 255,000 KRW (overvalued). Cautious scenario 54,515 KRW, optimistic scenario 195,205 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ALTEOGEN Inc (196170)?
ALTEOGEN Inc reported trailing-twelve-month revenue of about 204B KRW (latest available figure, as of Sep 19, 2026).
Does ALTEOGEN Inc pay a dividend?
ALTEOGEN Inc currently shows a dividend yield of about 0.15% relative to its recent price (as of Sep 19, 2026).
What growth is priced into ALTEOGEN Inc (196170)?
For today's price to be fair in a discounted-cash-flow model, ALTEOGEN Inc would have to grow free cash flow by +48.7 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +38.5 % per year. As of Sep 19, 2026.
What discount rate (WACC) does the fair value of 196170 use?
Our models discount ALTEOGEN Inc at 9.5 %: a base by market capitalisation (large), damped by beta 0.94, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ALTEOGEN Inc that is +48.7 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has ALTEOGEN Inc (196170) delivered so far?
Over the past 5 years revenue at ALTEOGEN Inc grew +38.5 % a year. The price currently implies +48.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ALTEOGEN Inc (196170) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into ALTEOGEN Inc (+48.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ALTEOGEN Inc (196170)?
The free-cash-flow yield on the price is 0.67 %: that much free cash flow ALTEOGEN Inc produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ALTEOGEN Inc (196170)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ALTEOGEN Inc it is 92,045 KRW per share (as of Sep 19, 2026), against a price of 255,000 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is ALTEOGEN Inc stock overvalued or undervalued in 2026?
As of Sep 19, 2026, 196170 trades above its calculated fair value: price 255,000 KRW, fair value 92,045 KRW, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 196170?
No. The price is what the market pays today (255,000 KRW); the fair value is what the company's own numbers justify (92,045 KRW). For ALTEOGEN Inc the two are 162,956 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ALTEOGEN Inc worth?
The market values ALTEOGEN Inc at about 14.8T KRW (market capitalisation, as of Sep 19, 2026). Per share that is 255,000 KRW; our models calculate a fair value of 92,045 KRW per share.
What do the bullish and bearish scenarios say about 196170?
Our models span a range for ALTEOGEN Inc: cautious scenario 54,515 KRW, base 92,045 KRW, optimistic 195,205 KRW per share (as of Sep 19, 2026, price 255,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ALTEOGEN Inc (196170)?
Balance-sheet figures for ALTEOGEN Inc (as of Sep 19, 2026): return on equity 25.2%, debt of 0.01 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 196170 from its 52-week high?
ALTEOGEN Inc trades at 255,000 KRW, about 55% below its 52-week high of 568,519 KRW (as of Sep 19, 2026). Distance from the high says nothing about value: that is what the fair value of 92,045 KRW is for.
Which stocks are comparable to ALTEOGEN Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ALTEOGEN Inc stock attractive at the current price?
The data as of Sep 19, 2026: price 255,000 KRW, calculated fair value 92,045 KRW (−64%), Quality Score 70/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 196170 calculated?
We run ALTEOGEN Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 92,045 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. ALTEOGEN Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ALTEOGEN Inc (196170)?
The closing price on Sep 21, 2026 was 255,000 KRW. Our model-based fair value is 92,045 KRW, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ALTEOGEN Inc right now?
A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (195,205 KRW). The favourable scenario is already priced in. The model range is unusually wide (54,515 KRW to 195,205 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of ALTEOGEN Inc
How large is the market capitalisation of ALTEOGEN Inc (196170)?
The market capitalisation of ALTEOGEN Inc is 14.8T KRW (≈ $10.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ALTEOGEN Inc (196170)?
The price-to-sales ratio of ALTEOGEN Inc is 72.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of ALTEOGEN Inc (196170)?
The dividend yield of ALTEOGEN Inc is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ALTEOGEN Inc (196170)?
The net margin of ALTEOGEN Inc is 65.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ALTEOGEN Inc (196170)?
The return on equity (ROE) of ALTEOGEN Inc is 25.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ALTEOGEN Inc (196170)?
On an EBIT basis the return on assets of ALTEOGEN Inc is 2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ALTEOGEN Inc (196170)?
The operating margin of ALTEOGEN Inc is 54.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ALTEOGEN Inc (196170)?
Revenue at ALTEOGEN Inc is growing −14.5% versus a year earlier (3y avg +95.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ALTEOGEN Inc (196170)?
Earnings per share at ALTEOGEN Inc are growing −41.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch ALTEOGEN Inc in the live analysis
One click puts ALTEOGEN Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
